Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Treasury Shares (2022 - 2026)

Compass Therapeutics' Treasury Shares history spans 5 years, with the latest figure at $1.6 million for Q1 2026.

  • On a quarterly basis, Treasury Shares fell 45.43% to $1.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.6 million, a 45.43% decrease, with the full-year FY2025 number at $1.0 million, down 72.7% from a year prior.
  • Treasury Shares hit $1.6 million in Q1 2026 for Compass Therapeutics, up from $1.0 million in the prior quarter.
  • Over the last five years, Treasury Shares for CMPX hit a ceiling of $3.8 million in Q4 2024 and a floor of $900000.0 in Q4 2022.
  • Historically, Treasury Shares has averaged $2.3 million across 5 years, with a median of $1.8 million in 2023.
  • Biggest five-year swings in Treasury Shares: soared 151.07% in 2024 and later crashed 72.7% in 2025.
  • Tracing CMPX's Treasury Shares over 5 years: stood at $900000.0 in 2022, then surged by 66.67% to $1.5 million in 2023, then surged by 151.07% to $3.8 million in 2024, then crashed by 72.7% to $1.0 million in 2025, then soared by 56.23% to $1.6 million in 2026.
  • Business Quant data shows Treasury Shares for CMPX at $1.6 million in Q1 2026, $1.0 million in Q4 2025, and $1.3 million in Q3 2025.